New tests monitor brain health during children’s heart surgery
April 25, 2012
- Two new monitoring methods may help detect brain damage in infants and children undergoing surgery to repair heart defects.
- One method, called autoregulation monitoring, can non-invasively determine periods during surgery, where blood flow to the brain may be low. A second test requires a small amount of blood to detect brain tissue injury during this kind of surgery.
- Both may guide future strategies to prevent brain damage.
EMBARGOED UNTIL Noon CT/1 pm ET, Wednesday, April 25
DALLAS, April 25, 2012 — A new monitoring method and blood test may provide early warnings when a child’s brain isn’t getting enough blood during heart surgery, according to new research presented during the American Heart Association’s Emerging Science Series webinar.
Brain injury occurs in 30 percent to 70 percent of infants and children undergoing repair of congenital heart defects . A congenital heart defect is a heart abnormality present at birth. Out of 1,000 live births in the United States, about 8 babies will have some kind of heart defect.
Previously, there has been no way to detect brain injury during surgery as it happens. This research was a multi-center observational pilot study to evaluate the feasibility of new monitoring strategies in a high-risk population of children with congenital heart disease.
Unlike other organs, the brain can automatically adjust blood vessel size to keep blood flow constant when blood pressure changes.
Researchers developed the “hemoglobin volume index,” a non-invasive monitoring technique to assess changes in the brain arteries. This monitoring technique allowed them to determine the lowest pressure before automatic adjustment was compromised. Researchers compared patient blood pressures with blood levels of glial fibrillary acidic protein (GFAP), an indicator of brain damage.
In 61 children (aged one week to 17 years) undergoing heart repair surgery, researchers found that:
- A lower limit of pressure autoregulation or LLA could be identified in 85 percent of the children and varied widely between patients; meaning that 85 percent are at risk of brain hypoperfusion.
- Both the hemoglobin volume index and GFAP became abnormal when the childrens’ heart and lung function was taken over by cardiopulmonary bypass during surgery, with the worst readings during rewarming, indicating the period of highest risk for the child undergoing heart surgery;
- The more time spent below LLA was associated with some increase in GFAP, suggesting a link between periods of decreased blood flow autoregulation and decreased brain blood flow and brain injury.
“Because the autoregulatory changes occurred almost concurrently with signs of brain injury, we may have a real-time measure where we can detect when injury is occurring and modify how we are managing the patients, for example being more aggressive with controlling blood pressure,” said R. Blaine Easley, M.D., lead author and associate professor in anesthesiology and pediatrics at Baylor college of Medicine in Houston.
The next step is a multi-center study that will correlate intra-operative test results with MRI changes and neurodevelopmental outcomes in the 18 months after surgery.
Co-authors are Jacky Jennings, Ph.D., M.D.; Kathleen Kibler, B.S.; Kenneth M. Brady, M.D.; Brittany Serratos, B.S.; Dean B. Andropoulos, M.D.; Marissa Brunetti, M.D.; Eugenie Heitmiller, M.D.; Jennifer K. Lee, M.D.; Michael Smith, B.S.; Pratima Dulloor, B.S.; Bradley S. Marino, M.D., M.P.P.; James Spaeth, M.D.; and Allen D. Everett, M.D. Author disclosures are on the manuscript.
The study is funded in part by an American Heart Association clinical research program grant from the Southwest affiliate.
For more about congenital heart defects visit heart.org/congenitalheartdefects .
Statements and conclusions of study authors published in American Heart Association scientific journals or presented at American Heart Association conferences are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .
NR12 – 1063 (ESS/Easley)
Additional resources are available in the right column.
For Media Inquiries: (214) 706-1173
Maggie Francis: (214) 706-1382; email@example.com
Carrie Thacker: (214) 706-1665; firstname.lastname@example.org
Julie Del Barto (broadcast): (214) 706-1330; email@example.com
For Public Inquiries: (800) AHA-USA1 (242-8721)